![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies
-
Article
Second cancer incidence in CLL patients receiving BTK inhibitors
Chronic lymphocytic leukemia (CLL) is associated with perturbed immune function and increased risk for second primary malignancies (SPM). Ibrutinib and acalabrutinib (BTKi) are effective therapies for CLL resu...
-
Article
Open AccessHypertension and incident cardiovascular events after next-generation BTKi therapy initiation
Post-market analyses revealed unanticipated links between first-generation Bruton’s tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early hypertension. Yet, whether this is seen with novel se...
-
Article
Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib
-
Article
Open AccessConsensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia
A significant body of literature has been generated related to the detection of measurable residual disease (MRD) at the time of achieving complete remission (CR) in patients with hairy cell leukemia (HCL). Ho...
-
Article
Correction: Evaluation of bleeding events in patients receiving acalabrutinib therapy
-
Article
Evaluation of bleeding events in patients receiving acalabrutinib therapy
-
Article
Comparison of karyotype scoring guidelines for evaluating karyotype complexity in chronic lymphocytic leukemia
-
Article
Open AccessHairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms